Dynavax Technologies Sees FY24 Net Product Revenue $265M-$280M Vs $290.628M Est.
$DVAX
Biotechnology: Pharmaceutical Preparations
Health Care
Dynavax Technologies Sees FY24 Net Product Revenue $265M-$280M Vs $290.628M Est.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $15.00 → $12.00 | Neutral → Sell | Goldman |
| 2/1/2024 | $20.00 | Neutral | Goldman |
| 9/27/2022 | $22.00 | Mkt Outperform | JMP Securities |
| 1/6/2022 | $38.00 | Buy | Goldman |
| 12/29/2021 | $23.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/31/2021 | $20.00 → $23.00 | Buy | HC Wainwright & Co. |
| 8/6/2021 | $19.00 | Buy | Goldman Sachs |
| 8/5/2021 | $16.00 → $20.00 | Buy | HC Wainwright & Co. |
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
DFAN14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
144 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously
Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00
JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. The Company also confirmed that Deep Track Capital ("Deep Track") has submitted a letter purporting to nominate four candidates to stand for election to the Dynavax Board of Directors at the Company's 2025 Annual Meeting of Stockholders.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2024.
EMERYVILLE, Calif., Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website
HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growthHepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market shareExpect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24 $200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commerci
Notes Investor Feedback Supporting Deep Track's Course of Action and Sharing Concerns with Company's Capital Allocation Strategy, Poor Governance, and Lack of Shareholder Perspective in the Boardroom Highlights Dynavax's Refusal to Reach a Constructive Resolution and Calls on Board to Stop Engaging in Petty "Activism Defense 101" Tactics Questions Company's Issuance of Expensive Convertible Notes in Recent Refinancing Instead of Using Cash on Hand Sets Record Straight Regarding Dynavax's Misleading Assertion That Deep Track is Seeking Control of the Board – Which is Simply False Reiterates Need for a Refreshed Board to Drive Critical Strategic Improvements and Protect the Long-Term Inte
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure$225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new moneyDynavax repurchased ~$8 million of the Company's common stock in connection with this transactionEMERYVILLE, Calif., March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Ex
EMERYVILLE, Calif., Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. ETBarclays 27th Annual Global Healthcare Conference on Tuesday, March 11 at 10:00 a.m. ETThe presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)